Previous 10 | Next 10 |
2024-05-31 16:11:42 ET Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $...
New York, New York--(Newsfile Corp. - May 31, 2024) - Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (NASDAQ: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by...
SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1 QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases w...
2024-05-30 12:24:45 ET Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patient...
Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)? Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive? Did you lose money in your investment in Biogen Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / May 30, 2...
2024-05-29 18:15:11 ET Summary Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which ...
Do you, or did you, own shares of Biogen Inc. (NASDAQ:BIIB)? Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive? Did you lose money in your investment in Biogen Inc.? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / May 29, 20...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)? Did you purchase your shares between February 3, 2022 and February 13, 2024, inclusive? Did you lose money in your investment in Bioge...
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea TOKYO and CAMBRIDGE, Mass., May 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized an...
2024-05-28 00:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...